Effect of Ferrous Ascorbate versus Liposomal iron on hemoglobinConcentration and Iron indices in 6 to 59 months age Children With Nutritional Iron-Deficiency Anemia:A Double blinded single centre Randomized clinical trial - Nil

Start Date01 Sep 2023

Sponsor / Collaborator-

NCT05489952 / RecruitingPhase 4IIT

Efficacy and Safety of Perioperative Iron Supplementation for Postoperative Rehabilitation of Geriatric Hip Fractures: a Multicenter, Randomized, Controlled Trial.

Geriatric hip fracture is an important disease that affects the health life of the elderly in China. Geriatric hip fracture is often complicated by a variety of comorbidities due to advanced age. And anemia is a common comorbidity. At present perioperative management of geriatric hip fracture, transfusion is only indicated for moderate and severe anemia, while no special medical intervention for mild anemia in China. More and more studies have found that iron can not only correct anemia, but also improve cardiac function, patients' quality of life and function. This study investigated the effect of perioperative iron supplementation on activity tolerance in elderly patients with hip fracture complicated with iron deficiency anemia. The study was a randomized, parallel controlled clinical study. Due to the requirements of the ethics committee, the unblinded setting was cancelled due to ethical considerations. Research will be grouped according to whether to accept iron supplementation treatment, are divided into 2 groups, respectively, iron treatment group and the traditional method. The method of randomization was stratified block randomization. The experimental group added to the intravenous iron sucrose during perioperative period according to the degree of iron deficiency. If there is still a iron deficiency or anemia at discharge, oral ferrous lactate is added after discharge. The outcomes include 6-minute walk distance, Harris score, EQ-5D score six months after surgery, perioperative blood transfusion rate, and so on in the two groups.

Start Date15 Sep 2022

Sponsor / Collaborator-

100 Clinical Results associated with Ferrous Sulfate/Ascorbic Acid

100 Translational Medicine associated with Ferrous Sulfate/Ascorbic Acid

100 Patents (Medical) associated with Ferrous Sulfate/Ascorbic Acid

11,002

Literatures (Medical) associated with Ferrous Sulfate/Ascorbic Acid

01 Aug 2024·Current pediatric reviews

Iron Deficiency Anemia: An Updated Review

Review

Author: Lam, Joseph M ; Wong, Alex H C ; Leung, Alexander K C ; Li, Xiuling ; Hon, Kam Lun

Background::

Worldwide, iron deficiency anemia is the most prevalent nutritional deficiency disorder and the leading cause of anemia in children, especially in developing countries. When present in early childhood, especially if severe and prolonged, iron deficiency anemia can result in neurodevelop- mental and cognitive deficits, which may not always be fully reversible even following the correction of iron deficiency anemia.

Objective::

This article aimed to familiarize physicians with the clinical manifestations, diagnosis, evaluation, prevention, and management of children with iron deficiency anemia.

Methods::

A PubMed search was conducted in February 2023 in Clinical Queries using the key term "iron deficiency anemia". The search strategy included all clinical trials (including open trials, non-randomized controlled trials, and randomized controlled trials), observational studies (including case reports and case series), and reviews (including narrative reviews, clinical guidelines, and meta-analyses) published within the past 10 years. Google, UpToDate, and Wikipedia were also searched to enrich the review. Only pa- pers published in the English literature were included in this review. The information retrieved from the search was used in the compilation of the present article.

Results::

Iron deficiency anemia is most common among children aged nine months to three years and during adolescence. Iron deficiency anemia can result from increased demand for iron, inadequate iron intake, decreased iron absorption (malabsorption), increased blood loss, and rarely, defective plasma iron transport. Most children with mild iron deficiency anemia are asymptomatic. Pallor is the most frequent presenting feature. In mild to moderate iron deficiency anemia, poor appetite, fatigability, lassitude, leth- argy, exercise intolerance, irritability, and dizziness may be seen. In severe iron deficiency anemia, tachy- cardia, shortness of breath, diaphoresis, and poor capillary refilling may occur. When present in early childhood, especially if severe and prolonged, iron deficiency anemia can result in neurodevelopmental and cognitive deficits, which may not always be fully reversible even with the correction of iron deficien- cy anemia. A low hemoglobin and a peripheral blood film showing hypochromia, microcytosis, and marked anisocytosis, should arouse suspicion of iron deficiency anemia. A low serum ferritin level may confirm the diagnosis. Oral iron therapy is the first-line treatment for iron deficiency anemia. This can be achieved by oral administration of one of the ferrous preparations, which is the most cost-effective medi- cation for the treatment of iron deficiency anemia. The optimal response can be achieved with a dosage of 3 to 6 mg/kg of elemental iron per day. Parenteral iron therapy or red blood cell transfusion is usually not necessary.

Conclusion::

In spite of a decline in prevalence, iron deficiency anemia remains a common cause of ane- mia in young children and adolescents, especially in developing countries; hence, its prevention is im- portant. Primary prevention can be achieved by supplementary iron or iron fortification of staple foods. The importance of dietary counseling and nutritional education cannot be overemphasized. Secondary prevention involves screening for, diagnosing, and treating iron deficiency anemia. The American Acad- emy of Pediatrics recommends universal laboratory screening for iron deficiency anemia at approximately one year of age for healthy children. Assessment of risk factors associated with iron deficiency anemia should be performed at this time. Selective laboratory screening should be performed at any age when risk factors for iron deficiency anemia have been identified.

01 Mar 2024·European journal of obstetrics & gynecology and reproductive biology: X

Treatment with intravenous iron in postpartum anaemia

Article

Author: Richards, Toby ; Lim, Jayne ; MacLean, Beth

The use of iron therapy is for the management of iron deficiency (ID), could the authors advise the baseline iron studies in their population and if they analyzed a subgroup with a ferritin < 15 ng/mL.The 6-wk period for follow up is very short.Symptoms of iron deficiency can overlap with the clin. presentation of anxiety or depression.In our experience, it is only after these 'iron deficiency symptoms' are managed that patients with gain the ability to cope and insight to help address their mental health symptoms, which usually also improve in a couple of months.Information on the iron deficiency at inclusion and longer follow-up will aid the data in the literature to support the need for a larger clin. trial on long-term mental health benefits in women.

01 Mar 2024·Journal of hazardous materials

Mitigating heavy metal volatilization during thermal treatment of MSWI fly ash by using iron(III) sulfate as a chlorine depleting agent

Article

Author: Han, Siyu ; Gao, Yuchen ; Chen, Kailun ; Jiang, Jianguo ; Meng, Fanzhi ; Lin, Li ; Li, Jinglin ; Qin, Weikai

In the thermal treatment of municipal solid waste incineration fly ash (FA), the presence of chlorides leads to the pronounced volatilization of heavy metals at high temperature, making heavy metals stabilization challenging. Conventional washing processes struggle to remove chlorides completely, and even minor residual chlorides can lead to significant heavy metal volatilization. This study innovatively applied iron(III) sulfate as a chlorine depleting agent, which can form FeCl₃ (boiling point 316 °C) and volatilize to remove the residual chlorides at below 500 °C, thus preventing the chlorination and volatilization of heavy metals at 600-1000 °C. Using water-washed FA to produce lightweight aggregate (LWA) preparation, after adding iron(III) sulfate, the volatilization rates of Pb and Cd at 1140 °C decreased to 5.4% and 9.3%, respectively, a reduction of 82.8% and 84.1% compared to before its addition. The LWA met standard requirements in both performance and heavy metal leaching toxicity. The mechanism was further studied through thermodynamic equilibrium calculations and heating experiments of pure chemicals. This study presents novel approaches and insights for suppressing the volatilization of heavy metals in FA at high temperature, thereby promoting the advancement of thermal treatment techniques and the safe, resourceful disposal of FA.

News (Medical) associated with Ferrous Sulfate/Ascorbic Acid

01 Dec 2023

·www.sciencedaily.com

Meteorites likely source of nitrogen for early Earth

Micrometeorites originating from icy celestial bodies in the outer Solar System may be responsible for transporting nitrogen to the near-Earth region in the early days of our solar system. Micrometeorites originating from icy celestial bodies in the outer Solar System may be responsible for transporting nitrogen to the near-Earth region in the early days of our solar system. That discovery was published today in Nature Astronomy by an international team of researchers, including University of Hawai'i at Manoa scientists, led by Kyoto University. Nitrogen compounds, such as ammonium salts, are abundant in material born in regions far from the sun, but evidence of their transport to Earth's orbital region had been poorly understood. "Our recent findings suggests the possibility that a greater amount of nitrogen compounds than previously recognized was transported near Earth, potentially serving as building blocks for life on our planet," says Hope Ishii, study co-author and affiliate faculty at the Hawai'i Institute of Geophysics and Planetology in the UH Manoa School of Ocean and Earth Science and Technology (SOEST). Like all asteroids, Ryugu is a small, rocky object that orbits the sun. The Japan Aerospace Exploration Agency's Hayabusa2 spacecraft explored Ryugu and brought material from its surface back to Earth in 2020. This intriguing asteroid is rich in carbon and has undergone significant space weathering caused by micrometeorite collisions and exposure to charged ions streaming from the sun. In this study, the scientists aimed to discover clues about the materials arriving near Earth's orbit, where Ryugu is currently located, by examining the evidence of space weathering in Ryugu samples. Using an electron microscope, they found that the surface of the Ryugu samples are covered with tiny minerals composed of iron and nitrogen (iron nitride: Fe4N). "We proposed that tiny meteorites, called micrometeorites, containing ammonia compounds were delivered from icy celestial bodies and collided with Ryugu," said Toru Matsumoto, lead author of the study and assistant professor at Kyoto University. "The micrometeorite collisions trigger chemical reactions on magnetite and lead to the formation of the iron nitride." The iron nitride was observed on the surface of magnetite, which consists of iron and oxygen atoms. When magnetite is exposed to the space environment, oxygen atoms are lost from the surface by the irradiation of hydrogen ions from the sun (solar wind) and by heating through micrometeorite impact. These processes form metallic iron on the very surface of the magnetite, which readily reacts with ammonia, creating ideal conditions for synthesis of iron nitride.

16 Nov 2023

·www.globenewswire.com

Alterity Therapeutics Announces Presentation of New Data Demonstrating Novel Mechanisms of ATH434

MELBOURNE, Australia and SAN FRANCISCO, Nov. 16, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced promising new data related to ATH434 was presented at the Society for Neuroscience that took place November 11-15, 2023, in Washington, D.C. The poster entitled, “Potent Antioxidant and Mitochondrial-protectant Effects of ATH434, a Novel Inhibitor of α-Synuclein Aggregation with Moderate Iron-binding Affinity,” presents new data indicating that ATH434 can preserve mitochondrial function after oxidative injury and exert direct anti-oxidant activity independent of its iron binding properties. These features were not observed with another iron binding agent approved for treating iron overload that was also investigated. The study was run under the direction of Dr. Daniel J. Kosman, Distinguished Professor of Biochemistry at the State University of New York at Buffalo. David Stamler, M.D., Chief Executive Officer of Alterity, commented, “These exciting new data underscore the potential of ATH434 as a treatment for neurodegenerative diseases, including Parkinson’s disease and related disorders. We have long known that ATH434 is able to reduce labile iron which, when elevated, can drive oxidative stress. The demonstrated mitochondrial protection may reveal additional mechanisms that augment its ability to slow disease progression. We are grateful for the valued contributions from our collaborators in Dr. Kosman’s laboratory at SUNY-Buffalo.” The study, authored by Dr. Danielle Bailey, investigated the efficacy of ATH434 and comparator agents as mitochondrial protectants using a menadione-induced model of oxidative stress in a neuronal cell line. A suite of in-solution assays detailed the mechanisms underlying ATH434’s direct antioxidant capacity. The poster presentation can be accessed on Alterity’s website under The Science page. About ATH434 Alterity’s lead candidate, ATH434, is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. ATH434 has been shown preclinically to reduce α-synuclein pathology and preserve neuronal function by restoring normal iron balance in the brain. As an iron chaperone, it has excellent potential to treat Parkinson’s disease as well as various Parkinsonian disorders such as Multiple System Atrophy (MSA). ATH434 successfully completed Phase 1 studies demonstrating the agent is well tolerated and achieved brain levels comparable to efficacious levels in animal models of MSA. ATH434 is currently being studied in two clinical trials: Study ATH434-201 is a randomized, double-blind, placebo-controlled Phase 2 clinical trial in patients with early-stage MSA and Study ATH434-202 is an open-label Phase 2 Biomarker trial in patients with more advanced MSA. ATH434 has been granted Orphan drug designation for the treatment of MSA by the U.S. FDA and the European Commission. About Alterity Therapeutics Limited Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases. The Company’s lead asset, ATH434, has the potential to treat various Parkinsonian disorders and is currently being evaluated in two Phase 2 clinical trials in Multiple System Atrophy. Alterity also has a broad drug discovery platform generating patentable chemical compounds to treat the underlying pathology of neurological diseases. The Company is based in Melbourne, Australia, and San Francisco, California, USA. For further information please visit the Company’s web site at www.alteritytherapeutics.com. Authorisation & Additional informationThis announcement was authorized by David Stamler, CEO of Alterity Therapeutics Limited. Investor and Media Contacts: AustraliaHannah Howlettwe-aualteritytherapeutics@we-worldwide.com+61 450 648 064 U.S.Remy Bernardaremy.bernarda@iradvisory.com +1 (415) 203-6386 Forward Looking Statements This press release contains "forward-looking statements" within the meaning of section 27A of the Securities Act of 1933 and section 21E of the Securities Exchange Act of 1934. The Company has tried to identify such forward-looking statements by use of such words as "expects," "intends," "hopes," "anticipates," "believes," "could," "may," "evidences" and "estimates," and other similar expressions, but these words are not the exclusive means of identifying such statements. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are described in the sections titled “Risk Factors” in the Company’s filings with the SEC, including its most recent Annual Report on Form 20-F as well as reports on Form 6-K, including, but not limited to the following: statements relating to the Company's drug development program, including, but not limited to the initiation, progress and outcomes of clinical trials of the Company's drug development program, including, but not limited to, ATH434, and any other statements that are not historical facts. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to the difficulties or delays in financing, development, testing, regulatory approval, production and marketing of the Company’s drug components, including, but not limited to, ATH434, the ability of the Company to procure additional future sources of financing, unexpected adverse side effects or inadequate therapeutic efficacy of the Company's drug compounds, including, but not limited to, ATH434, that could slow or prevent products coming to market, the uncertainty of obtaining patent protection for the Company's intellectual property or trade secrets, the uncertainty of successfully enforcing the Company’s patent rights and the uncertainty of the Company freedom to operate. Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Clinical ResultPhase 2Phase 1Orphan Drug

25 Oct 2023

·www.prnewswire.com

Renibus Announces First Patient Enrolled in PROTECT Phase 3 Study of RBT-1 to Reduce Post-operative Complications After Cardiothoracic Surgery

Pivotal trial will evaluate the effect of RBT-1 as a preconditioning agent in people undergoing cardiothoracic surgeryEstimated 600K CABG and valve repair surgeries in US/year, creating a large initial market for RBT-1PROTECT enrollment on track, NDA filing anticipated early 2026 SOUTHLAKE, Texas, Oct. 25, 2023 /PRNewswire/ -- Renibus Therapeutics® ("Renibus"), a clinical-stage biopharmaceutical company focusing on the prevention and treatment of cardio-renal and metabolic diseases, today announced that the first patient has been dosed in the pivotal Phase 3 PROTECT trial of RBT-1, the Company's first-in-a-new-class preconditioning agent under investigation to reduce post-operative complications following cardiothoracic surgery. PROTECT is expected to be conducted at approximately 35 sites in the United States and Canada. Continue Reading Post-operative complications from cardiothoracic surgery represent a major unmet medical need. In the United States (US), there are approximately 600,000 CABG, valve repair, and related procedures conducted annually, with 66% of patients having complications that result in $6.5 billion in unnecessary healthcare costs. This represents a significant and growing initial market for RBT-1, which if approved, would be the first and only approved pharmacological therapy to reduce the risk of post operative complications following cardiothoracic surgery. RBT-1 (stannic protoporfin/iron sucrose), a fixed dose combination product given once intravenously over 1-2 hours, 24-48 hours before surgery, is a potent inducer of anti-inflammatory, antioxidant and iron-scavenging pathways. In a completed Phase 2 study, RBT-1 demonstrated statistically significant positive data in primary and several secondary endpoints, with reduced time in the ICU, shortened patient recovery time and fewer hospital readmissions. "We are pleased to initiate our PROTECT Phase 3 study of RBT-1. This milestone represents a significant step towards addressing the unmet needs associated with post-operative complications after cardiothoracic surgery, and underscores our commitment to transforming this treatment landscape," said Frank Stonebanks, Co-CEO of Renibus. "With our pivotal trial now underway in our PROTECT program, we are considering ways to expand the opportunity with RBT-1 across a wide spectrum of procedures and post-operative complications, including potentially transplant surgeries, TAVR's (trans aortic valve replacements) and thoracic aortic aneurysms. We believe that RBT-1 has broad "pipeline-in-a-product" potential, and we look forward to executing well in Phase 3 and bringing our product to patients in need." PROTECT is a Phase 3, Rand omized, Double-Blind, Placebo-Controlled S tudy to Evaluate the Effect of RBT-1 on Reducing the Risk of Post-Operative Complica tions in Subjects Undergoing Cardiac Surgery. The study is a randomized, double-blind, multi-center, placebo-controlled trial evaluating the effect of RBT-1 in approximately 400 patients. The primary endpoint is a severity-based composite hierarchy using the Win-Ratio or Finkelstein-Schoenfeld Method that includes the following: death, AKI requiring dialysis, ICU days, and 30-day cardiopulmonary readmission rates. Secondary and exploratory objectives include time on the ventilator, need for blood products, new onset atrial fibrillation, delirium, hospital length of stay, cost effective analyses and safety. Top line results are expected mid-2025. Charles A. Mack, MD, FACS, Associate Professor of Cardiothoracic Surgery, New York-Presbyterian Hospital, Weill Cornell Medicine, added, "The cardiac surgery community is grateful for Renibus' commitment to bringing a new treatment option forward for patients undergoing cardiac surgery. RBT-1 is a potentially transformational pre-conditioning product, and I am enthusiastic about the initial results demonstrated in our patients." About RBT-1 RBT-1 (stannic protoporfin/iron sucrose) is a potent inducer of anti-inflammatory, antioxidant and iron-scavenging pathways currently in Phase 3 [NCT # 06021457] for its lead indication to reduce post-operative complications following cardiothoracic surgery. Renibus completed the Phase 2 study of RBT-1 (NCT04564833) in February 2023 and announced positive final results from this study in May 2023. In October 2023, Renibus initiated enrollment and administration of RBT-1 in its PROTECT Phase 3 pivotal study. RBT-1 was granted Breakthrough Therapy designation status from the U.S. FDA to reduce the risk of complications in patients undergoing cardiothoracic surgery. About Renibus Therapeutics Renibus is a clinical stage biopharmaceutical company dedicated to treating, improving and extending patients' lives by developing products to prevent disease progression, improve outcomes and protect against organ damage associated with cardiorenal and metabolic diseases. Renibus' first-in-class lead program is RBT-1, currently being evaluated in a pivotal Phase 3 PROTECT study. RBT-3 is a novel, low molecular weight iron nanoparticle that has the potential to rapidly resolve iron deficiency and may reduce the risk of cisplatin-induced nephrotoxicity. RBT-9 (stannic protoporfin) is a potent anti-inflammatory and antioxidant drug with broad spectrum anti-viral properties. It has been investigated in a 42-patient Phase 2, randomized, placebo-controlled trial in high-risk patients with COVID-19. The data from this trial indicated the RBT-9 has the potential to significantly improve clinical outcomes in life threatening viral infections. Additional pre-clinical work is underway to help inform the clinical development strategy. For more information, please visit the Company's website at and engage with us on LinkedIn. Investor and Media Contact: Amy Conrad Juniper Point [email protected] 858-914-1962 Business Development Contact Frank Stonebanks Co-CEO, Renibus [email protected] SOURCE Renibus Therapeutics

Phase 2Phase 3Breakthrough Therapy

100 Deals associated with Ferrous Sulfate/Ascorbic Acid

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB13257

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Anemia, Iron-Deficiency	CN	-	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


EHA2022	Not Applicable	COVID-19	60	Sucrosomial® iron	ugiopcivif(hidhzpfvbc) = bvhkaujmpw tlxwatmkbg (elcitgfncd ) View more	-	10 Jun 2022
				iron oral formulation (No iron support)	ugiopcivif(hidhzpfvbc) = jsbcbiapjp tlxwatmkbg (elcitgfncd ) View more
ASN2021	Not Applicable	FGF23	20	EPO with parenteral Fe supplement	aebmylwgpk(bhzxdfoivc) = rwopeexeww nbjfrnyhzz (lhxyxhxnvf )	Positive	27 Oct 2021
				EPO without parenteral Fe supplement	aebmylwgpk(bhzxdfoivc) = aiuhnhxmfh nbjfrnyhzz (lhxyxhxnvf )
ASN2020	Not Applicable	Chronic Kidney Diseases	170	Iron isomaltoside (HDLF1)	zcpejuvymt(shnoagugnf) = thurxlwlyx kvggfkgmmz (nylbgpslzs ) View more	Positive	19 Oct 2020
ERA2020	Not Applicable	HF \| diabetes	2,141	High-dose intravenous iron	npqrmsuiuf(qvkgngmsxb) = uuwflksbnq vrlfjjntzq (tayligwlid )	Positive	06 Jun 2020
				Low-dose intravenous iron	npqrmsuiuf(qvkgngmsxb) = inpumdnnsf vrlfjjntzq (tayligwlid )
EHA2019	Not Applicable	-	36	Iron Sulphate	lkkpnxrxof(lxwchakcth) = ktnahkgosc hdtdifilhm (astxjjweot )	-	16 May 2019
				Sucrosomial® Iron	lkkpnxrxof(lxwchakcth) = nlauqydncc hdtdifilhm (astxjjweot )
EHA2019	Not Applicable	Myelodysplastic Syndromes	45	Group A (sodium ferrigluconate)	kiunqnzpmx(ixhxtuypof) = uoxwcnrkdk wgsrwztabz (czblfoepzl ) View more	-	16 May 2019
				Group B (sucrosomial iron)	kiunqnzpmx(ixhxtuypof) = qehcjdqohi wgsrwztabz (czblfoepzl ) View more
ASN2018	Not Applicable	Hodgkin's Lymphoma MDA-LDL \| NTBI \| TSAT ... View more	-	Oral ferrous sulfate 105mg	jfeimuskzv(qqsrwwfeqx) = gchtlleavp krdhdgolba (rcijpiyrhp, 104 - 320) View more	Positive	23 Oct 2018
				Oral Iron Administration (OIA)	luyvqjtvel(rgqdwkpneu) = brvggehddy rxhnjovugn (hrrfcsguux, 68 - 124)
ASN2018	Not Applicable	Hypophosphatemia FGF23	-	IV ferric carboxymaltose	tkirxuykhc(dwryktoyoz) = numbness, tingling and muscle cramps nbaesbxghv (ogxrbxyzjc )	Negative	23 Oct 2018
				Oral phosphorus supplementation
NCT00992823 (Pubmed \| BMC Public Health)	Not Applicable	Anemia	99	iron supplementation (Weekly Group)	hasgkvopyn(pzjzmdsppd) = pbiuwdfazc nzosulokei (olekzzezas ) View more	-	10 Jan 2013
				iron supplementation (Cyclical Group)	hasgkvopyn(pzjzmdsppd) = gfsyehqnxw nzosulokei (olekzzezas ) View more
NCT01092377 (Pubmed \| Int J Psychophysiol)	Not Applicable	Iron deficiency	321	Iron supplementation	uxchhonjie(wpvfjqshvd): OR = 2.31 (95% CI, 1.13 - 4.73)	-	01 Jan 2013
				iron supplementation (Placebo)

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis